Cytosine deaminase (CD) is found in prokaryotes and fungi (but not higher eukaryotes) and catalyzes the deamination of cytosine and 5-¯uorocytosine to uracil and 5-¯uorouracil, respectively. The former activity is an important function within the pyrimidine-salvage pathway, while the latter activity allows the formation of a cytotoxic chemotherapeutic agent from a non-cytotoxic precursor. Recombinant bacterial CD from Escherichia coli has been subcloned, overexpressed, puri®ed and crystallized for structural analysis. The crystals belong to space group R32, with unit-cell parameters a = b = 109.1, c = 240 A Ê and diffract to at least 1.5 A Ê resolution at a synchrotron X-ray source. There is one enzyme subunit per asymmetric unit and the Matthews coef®cient V M is 2.8 A Ê 3 Da À1 , corresponding to a solvent content of 56%. Selenomethioninecontaining protein has been prepared and crystallized for MAD phasing.
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Introduction
Cytosine deaminase (E.C. 3.5.4.1) catalyzes the deamination of cytosine to uracil and ammonia. Cells expressing cytosine deaminase are sensitive to the nucleoside analog 5-¯uorocytosine (5FC) owing to their ability to convert that substrate analogue to the toxic metabolite 5-¯uorouracil (5FU). 5FU and its deoxyribonucleoside (¯uorodeoxyuridine, FUdR) are potent inhibitors of DNA synthesis in their triphosphorylated forms and are widely used in cancer treatment (DiPiro et al., 1997) . Therefore, cytosine deaminase is being investigated for gene-therapy applications owing to the absence of this gene in humans (Austin & Huber, 1992; Hirschowitz et al., 1995; Huber et al., 1993; Kievit et al., 1999; Mullen et al., 1992) . In addition, since most fungi express cytosine deaminase, 5-FC is commonly used as an antifungal drug (DiPiro et al., 1997) .
Cytosine deaminase is a distinct enzyme from cytidine deaminase, as that enzyme is completely dissimilar in sequence, size, substrate preferences and kinetic properties (Erbs et al., 1997; Ipata & Cercignani, 1978; Kurtz et al., 1999) . A comparision of E. coli and Saccharomyces cerevisiae cytosine deaminases also reveals signi®cant differences between these enzymes at the primary amino-acid sequence, monomer molecular mass, quaternary structure and substrate-af®nity level, indicating that they are distinct enzymes (Erbs et al., 1997; Kievit et al., 1999) . The bacterial enzyme (bCD) from E. coli is a hexamer of approximately 426 amino acids per subunit (see x2 below), giving a mass of approximately 300 kDa for the active enzyme complex. The yeast enzyme (yCD) is a homodimer consisting of 17 kDa per subunit. Several studies have indicated that the yeast enzyme is more ef®cient at catalyzing the conversion of 5FC to 5FU, in part because of its lower K M for the 5FC substrate (0.8 mM for yeast, 17.9 mM for E. coli; Hayden et al., 1998; Kievit et al., 1999) . These same studies have also indicated that the bacterial enzyme may be more thermostable than its yeast counterpart, but precise comparisons have not been reported and recent studies have not supported this observation (Peter Senter, private communication).
bCD is a metalloenzyme that has been reported to be dependent on Fe 2+ for maximum activity (Porter & Austin, 1993) . Removal of the ferrous ion by treatment with o-phenanthrolein results in inactivation of the enzyme; activity is fully restored by addition of free Fe 2+ . Substitution with zinc for the activesite iron also restores activity, but only to approximately 10% of its maximal velocity and k cat /K M values (Porter, 2000) . The enzyme is capable of deaminating a wide range of cytosine derivatives with varying ef®ciency, including cytosine, 2-thiocytosine, 6-azacytosine, 4-azacytosine and 5-¯uorocytosine (Porter, 2000) . crystallization papers 2. Methods and results
Subcloning, expression and purification
The E. coli cytosine deaminase gene was ampli®ed by PCR from pCD2, a plasmid kindly provided by R. Michael Blaese. The primers for PCR were 5 H -GTTATTCGC-CATGGCTAGCCT-3 H (forward with an NcoI site at the start codon) and 5 H -GTCGTTCAAGCTTTGTAATCG-3 H (reverse with HindIII site just 3 H to the stop codon). The uncut PCR product was initially cloned into pCR2.1-TOPO (Invitrogen) and the cytosine deaminase gene was then subcloned as an 1.3 kbp NcoI/HindIII fragment into pET-HT (Brady et al., 1996) . Genes cloned in frame into the NcoI site of pET-HT are fused with sequences to provide a histidine tag at the N-terminus of expressed proteins. The resulting plasmid was sequenced and designated pETHT:bCD and contains an alteration in the bCD start codons from Val-Ser to Met-Ala. For protein expression, pETHT:bCD was transformed into the E. coli strain BL21(DE3).
Cells constitutively expressing bCD were grown in LB media at 310 K until an OD 600 greater than 1.5 was achieved. The cells were harvested by centrifugation at 2000g for 10 min at 277 K and the cell pellets were resuspended in 50 ml lysis buffer (300 mM NaCl, 20 mM Tris±HCl pH 7.0, 5 mM imidazole, 0.2% Triton X-100, 0.5 mM PMSF). Lysozyme was added to 0.5 mg ml À1 , followed by 30 min incubation on ice. Cells were sonicated using a Branson soni®er 250 equipped with a macrotip set to pulse for 5±8 min at 277 K with the duty cycle set to 40%. The cell lysates were clar-i®ed by centrifugation at 20 000g for 30 min at 277 K and the clari®ed supernatant was passed through a 0.45 mm syringe ®lter. The ®ltered supernatant was added to 5 ml packed bed volume of TALON metal af®-nity resin (Clontech) equilibrated with ten bed volumes lysis buffer and incubated at 295 K for 30 min with rocking at 10 rev min À1 . The af®nity resin was washed three times with ten bed volumes of wash buffer (300 mM NaCl, 20 mM Tris±HCl pH 7.0, 10 mM imidazole, 0.5 mM PMSF) and the bCD protein was eluted from the resin with 3 Â 15 ml elution buffer (300 mM NaCl, 150 mM imidazole, 20 mM Tris±HCl pH 7.0, 0.5 mM PMSF). The eluted fractions were concentrated and dialyzed into storage buffer (100 mM NaCl, 20 mM Tris±HCl pH 8.0, 1 mM DTT, 1 mM EDTA) prior to loading onto a Superdex 200 HiLoad16/60 sizing column (Pharmacia) equilibrated with storage buffer. Peak bCD fractions were analyzed by SDS±PAGE, pooled and concentrated to 30 mg ml À1 , with typical yields of 60±70 mg of highly pure His-tagged bCD ($99%) obtained per litre of bacterial culture. Thrombin cleavage of the N-terminal histidine tag was conducted for 3 h at 310 K using 0.5 U biotinylated thrombin (Novagen) per milligram of bCD protein in thrombin cleavage buffer (150 mM NaCl, Tris±HCl pH 8.4, 2.5 mM CaCl 2 ). Biotinylated thrombin was removed by 30 min incubation at 296 K with 10 ml streptavidin-conjugated agarose beads per unit of thrombin followed by gravity¯owthrough column puri®cation. The column owthrough was dialysed into storage buffer and the protein concentration estimated by Bradford assay. Analysis of the protein molecular weight by size-exclusion chromatography against a variety of protein standards indicate that the protein is a functional hexamer (Fig. 1) , rather than a tetramer or pentamer as previously hypothesized (Katsuragi et al., 1986; Kievit et al., 1999) . This result is consistent with the space group and asymmetric unit of the crystallized protein (see below) and has been con®rmed as part of the crystallographic structure determination (data not shown).
For inducible expression of the selenomethionine-derivatized protein, pETHT:bCD was digested with XbaI/XhoI and the fragment containing the fusion protein was subcloned into pET15b (Novagen). Semethionine-containing bCD (SeMet-bCD) was expressed in minimal media from E. coli strain BL21(DE3) adapted for growth with methioninepathway inhibition (Doublie, 1997) . Cells were grown in minimal media at 310 K to an OD 600 of 0.6 and the following amino acids were added to inhibit methionine biosynthesis: 100 mg l À1 lysine, 100 mg l À1 threonine, 100 mg l À1 phenylalanine, 50 mg l À1 leucine, 50 mg l À1 isoleucine, 50 mg l À1 valine and 75 mg l À1 selenomethionine. Following 15 min incubation at 310 K, isopropyl-thio--d-galactosidase (IPTG) was added to a ®nal concentration of 0.5 mM and the cultures were grown at 310 K for 12 h postinduction. SeMet-bCD was puri®ed analogously to native bCD. Incorporation of selenium was veri®ed by mass spectrometry.
Crystallization and preliminary X-ray analysis.
Initial crystals of bCD were grown from Hampton sparse-matrix screens (Jancarik & Kim, 1991) by the method of vapour diffusion in hanging drops at room temperature. Crystals were optimized around the initial conditions using grids that varied protein and precipitant concentrations, pH and ionic strength. The optimized crystallization conditions produced large crystals from a protein solution at 10 mg ml À1 equilibrated against a reservoir solution consisting of 11±14% PEG 8000, 0.1 M HEPES pH 7.3±7.7 and 0.2 M MgCl 2 . Crystals grew as large 0.4 Â 0.4 Â 0.5 mm rhombs in 7±10 d in approximately 2% of the drops. Crystals were¯ash-cooled for data collection after sequential transfers to a ®nal arti®cial mother liquor containing 30% glycerol, 15% PEG 8000, 0.1 M HEPES pH 7.5, 0.2 M MgCl 2 .
The crystals diffract to high resolution on beamline 5.0.2 at the Advanced Light Source Synchrotron facility, with spots visible to beyond 1.5 A Ê resolution. A native data set was collected at that beamline using a 2 Â 2 CCD area detector (ADSC). Data were processed and scaled using the DENZO/SCALEPACK program packages (Otwinowski & Minor, 1997) . The crystals belong to space group R32, with unit-cell parameters a = b = 109.1, c = 240 A Ê (hexagonal convention). Statistics for the native data set are shown in Table 1 . Assuming that the asymmetric unit corresponds to a single protein subunit (and that the protein crystallization papers hexamer is produced by crystallographic threefold and dyad symmetry axes), the Matthews coef®cient V M (Matthews, 1968 ) is approximately 2.8 A Ê 3 Da À1 , corresponding to a solvent content of 56%. This assignment has been con®rmed by determination of the number of methionine residues in the asymmetric unit during the initial stages of MAD data collection and phase calculations, with nine selenomethionine peaks observed per asymmetric unit, in agreement with the protein subunit sequence (unpublished data). The presence of a single protein subunit in the asymmetric unit of space group R32 appears to preclude a pentameric protein assembly.
